Delivery Order SPE2DB22D9316-SPE2DB25FYP94
- Not listed
- The U.S. Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. for LENVIMA 20 mg daily dose (60-count supply) valued at $11,353.77 on August 21, 2025, with completion expected by September 12, 2025. This firm fixed-price delivery order was awarded without set-aside designation to the Park Ridge, Illinois-based woman-owned small business pharmaceutical wholesaler. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc. for the supply of Lenvima 8 mg daily dose tablets (60-count) with an ultimate completion date of October 7, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under the company's existing Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $124,891.53 for LENVIMA 20 mg daily dose medication (60-unit supply) by the Defense Logistics Agency's Medical Supply Chain on September 15, 2025. This delivery order, which carries no set-aside designation, is part of DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB...
- The Defense Logistics Agency awarded a delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 14 mg daily dose medication (60-count supply). This firm fixed-price delivery order, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a tactical fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $11,006.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of LENVIMA 10 MG DAILY DOSE 30S, a prescription medication, with a period of performance through August 5, 2024. This delivery order contract was issued under DMS Pharmaceutical Group's existing, single-award indefinite delivery contract...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $34,061.31 to DMS Pharmaceutical Group Inc. for the supply of Lenvima 8 mg daily dose tablets (60-count). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge location with an ultimate completion date of October 6, 2025. This award was made without a set-aside designation, and the contract was...
- The Defense Logistics Agency awarded a delivery order valued at $11,353.77 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 12 mg daily dose in 90-count quantities. The award, issued on August 7, 2025, with an ultimate completion date of August 28, 2025, utilizes firm fixed-price terms without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 17, 2025, for LENVIMA 8 mg daily dose medication (60-count supply). The contract is valued at $29,624.58 and operates under a firm fixed-price delivery order structure with an ultimate completion date of October 8, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order, valued at $22,013.90, is for the supply of Lenvima 10 mg daily dose medication. The award is part of a larger indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA, valued at up to $499,999,999, which allows the DLA to issue firm fixed-price delivery orders for a wide...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lenvima 8 mg daily dose tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $11,353.77, was awarded on September 10, 2025, with an ultimate completion date of October 1, 2025. The contract contains no set-aside designation, allowing DMS Pharmaceutical Group to compete...
- SPE2DB22D9316Indefinite Delivery Contract
- SPE2DB22D9316-SPE2DB25FYP94Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $22,707.56 to DMS Pharmaceutical Group Inc. for the supply of LENVIMA 10 mg daily dose (30-count) medication. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without set-aside designation. The delivery order is scheduled for completion by September 22, 2025, and represents a discrete fulfillment under the company's broader pharmaceutical supply framework with the federal government. This award is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the Defense Logistics Agency valued at $499.999 billion through November 2026, which authorizes firm fixed-price delivery orders for pharmaceutical products supporting military health facilities worldwide. The company has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently winning contracts for a diverse portfolio including oncology treatments, biologics, vaccines, and specialty medications. LENVIMA, a targeted cancer therapy, aligns with the company's demonstrated capabilities in delivering specialized pharmaceutical products to Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.7k | 8/29/25 |